FLT3 and acute myeloid leukemia: In conclusion, with the limitations of a retrospective study, FLAI-5 seems to be an effective therapy for NPM1 mut AML patients, regardless of FLT3-ITD status and may not require the application of HSCT in first CR, especially in patients achieving a rapid MRD clearance [22,29].